Clinical- and cost-effectiveness of LDL particle-guided statin therapy: A simulation study

Atherosclerosis

Volumn 236, Issue 1, 2014, Pages

  Folse, Henry J ^a   Goswami, Devesh ^a   Rengarajan, Badri ^a   Budoff, Matthew ^b   Kahn, Richard ^c  

^a Archimedes Inc   (United States)

^b LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cholesterol; Hypercholesterolemia; Hyperlipoproteinemia; LDL particle; LDL P; Lipoprotein; Statin

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN PARTICLE; SIMVASTATIN; UNCLASSIFIED DRUG; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; VIRTUAL REALITY; BIOLOGICAL MODEL; BLOOD; CARDIOVASCULAR DISEASES; COMORBIDITY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; COST CONTROL; DIABETES MELLITUS; DIET THERAPY; DRUG COST; DRUG SUBSTITUTION; DYSLIPIDEMIAS; ECONOMICS; HYPERCHOLESTEROLEMIA; LIFESTYLE; MEDICARE; MORTALITY; NUCLEAR MAGNETIC RESONANCE; PROCEDURES; RISK; RISK REDUCTION; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; COMPUTER SIMULATION; COST SAVINGS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG COSTS; DRUG SUBSTITUTION; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIFE STYLE; LIPOPROTEINS, LDL; MEDICARE; MODELS, CARDIOVASCULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PYRROLES; QUALITY-ADJUSTED LIFE YEARS; RISK; RISK REDUCTION BEHAVIOR; SIMVASTATIN; TREATMENT OUTCOME; UNITED STATES;

EID: 84905861875     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.06.027     Document Type: Article

References (46)

1. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
2. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006, 26:847-870.
3. Cromwell W.C., Barringer T.A. Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. Curr Cardiol Rep 2009, 11:468-475.
4. Otvos J.D., Jeyarajah E.J., Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 90:22-29.
5. Cromwell W.C., Otvos J.D. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol 2006, 98:1599-1602.
6. Rosenson R.S., Davidson M.H., Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010, 213:1-7.
7. Cromwell W.C., Otvos J.D., Keyes M.J., Pencina M.J., Sullivan L., Vasan R.S., et al. LDL particle number and risk of future cardiovascular disease in the framingham offspring study-implications for LDL management. JClinical Lipidol 2007, 1:583-592.
8. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 2006, 113:1556-1563.
9. Otvos J.D., Mora S., Shalaurova I., Greenland P., Mackey R.H., Goff D.C. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. JClinical Lipidol 2011, 5:105-113.
10. Sniderman A.D., Islam S., Yusuf S., McQueen M.J. Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the interheart study. Atherosclerosis 2012, 225:444-449.
11. Sampson U.K., Fazio S., Linton M.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012, 14:1-10.
12. Rosenson R.S., Underberg J.A. Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther 2013, 1-15.
13. Rosenson R.S., Otvos J.D., Hsia J. Effects of Rosuvastatin and Atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome a randomized, double-blind, controlled study. Diabetes Care 2009, 32:1087-1091.
14. Sniderman A.D. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. JClinical Lipidol 2008, 2:36-42.
15. Law M.R., Wald N.J., Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423.
16. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. NEngl J Med 2007, 357:1301-1310.
17. Hausenloy D., Yellon D. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J 2008, 84:590-598.
18. Carey V.J., Bishop L., Laranjo N., Harshfield B.J., Kwiat C., Sacks F.M. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 2010, 106:757-763.
19. Schlessinger L., Eddy D.M. Archimedes: a new model for simulating health care systems-the mathematical formulation. JBiomed Inform 2002, 35:37-50.
20. Eddy D.M., Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003, 26:3093-3101.
21. Eddy D.M., Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care 2003, 26:3102-3110.
22. Schuetz C.A., van Herick A., Alperin P., Peskin B., Hsia J., Gandhi S.K. Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. JMed Econ 2012, 15:1118-1129.
23. van Herick C.A., Schuetz C.A., Alperin P., Bullano M.F., Balu S., Gandhi S. The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model. Clinicoecon Outcomes Research: CEOR 2012, 4:337.
24. Eddy D., Cohen M.-D., Shum K., Dziuba J. Validation methodology and results: ARCHeS simulator 2.5: Archimedes, Inc 2013.
25. Schlessinger L., Eddy D. Predict validation cards trial: Archimedes, Inc 2011, [accessed Jan. 2014]. http://https://archimedesmodel.com/tech-reports.
26. Centers for Disease Control and Prevention (CDC) National center for health statistics (NCHS). Natl Health Nutr Exam Surv Data 1999-2008, [accessed March 2013]. http://www.cdc.gov/nchs/nhanes.htm.
27. Bild D.E., Bluemke D.A., Burke G.L., Detrano R., Roux A.V.D., Folsom A.R., et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002, 156:871-881.
28. Neter J.E., Stam B.E., Kok F.J., Grobbee D.E., Geleijnse J.M. Influence of weight reduction on blood pressure a meta-analysis of randomized controlled trials. Hypertension 2003, 42:878-884.
29. National health and nutrition examination survey data 2007-2008.
30. Eddy D., Cohen M.-D., Dziuba J. Care processes: calibration methodology and results: ARCHeS simulator 2.5: Archimedes, Inc 2013.
31. Altman D.G., Andersen P.K. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999, 319:1492-1495.
32. http://Healthwarehouse.com/.
33. Services CfMaM Physicians fee schedule 2013.
34. Medicare limited data set (LDS) 2009.
35. Samsa G.P., Bian J., Lipscomb J., Matchar D.B. Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999, 30:338-349.
36. Esposito D., Bagchi A.D., Verdier J.M., Bencio D.S., Kim M.S. Medicaid beneficiaries with congestive heart failure: association of medication adherence with healthcare use and costs. Am J Manag Care 2009, 15:437-445.
37. Wu E.Q., Birnbaum H.G., Mareva M., Tuttle E., Castor A.R., Jackman W., et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005, 21:1693-1699.
38. Sullivan P.W., Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak 2006, 26:410-420.
39. Garber A.J., Abrahamson M.J., Barzilay J.I., Blonde L., Bloomgarden Z.T., Bush M.A., et al. American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013, 19:1-48.
40. Davidson M.H., Ballantyne C.M., Jacobson T.A., Bittner V.A., Braun L.T., Brown A.S., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. JClinical Lipidol 2011, 5:338-367.
41. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic riskconsensus conference report from the american diabetes association and the american college of cardiology foundation. JAm Coll Cardiol 2008, 51:1512-1524.
42. Contois J.H., McConnell J.P., Sethi A.A., Csako G., Devaraj S., Hoefner D.M., et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices. Clin Chem 2009, 55:407-419.
43. Cole T.G., Contois J.H., Csako G., McConnell J.P., Remaley A.T., Devaraj S., et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC lipoprotein and vascular diseases division working group on best practices. Clin Chem 2013, 59:752-770.
44. Sniderman A.D., Williams K., Contois J.H., Monroe H.M., McQueen M.J., de Graaf J., et al. Ameta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovasc Qual Outcomes 2011, 4:337-345.
45. Stone N.J., Robinson J., Lichtenstein A.H., Merz C.N.B., Lloyd-Jones D.M., Blum C.B., et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in AdultsA report of the american college of Cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2013, 63:2889-2934.
46. Grundy S.M. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. JClinical Lipidol 2013, 7:561.